Notable healthcare headlines for the week: AstraZeneca, Eli Lilly, Bristol Myers in focus

Merca2.es

Factuality

Ownership

The analysts of the German bank Berenberg reiterate the rating of the US pharmaceutical company Bristol-Myers Squibb in Keeping, but they cut their target price to 55.0 from the previous $60.0. The evaluation of the pharmaceutical company is still low, as the growth prospects must improve: Bristol-Myers is listed with a PER for 2026 estimated 7.9 times, in line with the US sector, and an EV/NPV of 0.76 times compared to the US average of 0.98 ti…